Yajing Chen

“Return our China commercial business to growth, maintain a disciplined cost structure, and fund our highest value global program. Our third quarter results showed progress on all three.”

“As Samantha and Rafael described, Xilab is entering the next phase of its evolution. From a financial perspective, our objective is straightforward, build on our commercially profitable business while investing with discipline behind the innovation that will drive our next stage of growth.”

“Our Our quarter one results reflect the near-term dynamics just described. First quarter total product revenue declined 6% year-over-year to $99.6 million, driven by lower Bejula sales partially offset by continued growth from Zagdura and New Zealand.”

“Fourth quarter, total revenue grew 17% year-over-year to $127.6 million, driven by strong contributions from Zagduro and Nuzaira. Zagduro performance reflected strong patient demand and expanding hospital adoption. though supply constraints during the year limited the full realization of underlying demand.”

“Now I will discuss highlights from our second quarter 2025 financial results compared to the prior year period.”